153 related articles for article (PubMed ID: 28121744)
1. Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma.
Ozeki M; Nozawa A; Kanda K; Hori T; Nagano A; Shimada A; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):e328-e331. PubMed ID: 28121744
[TBL] [Abstract][Full Text] [Related]
2. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma.
Gabor KM; Sapi Z; Tiszlavicz LG; Fige A; Bereczki C; Bartyik K
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28843050
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma.
Joseph J; Wang WL; Patnana M; Ramesh N; Benjamin R; Patel S; Ravi V
Clin Sarcoma Res; 2015; 5():22. PubMed ID: 26500758
[TBL] [Abstract][Full Text] [Related]
5. Oral Pseudomyogenic Hemangioendothelioma: Case Report and Review of the Literature.
Shackelford AJ; Canterbury CR; Perrino MA; Wang J; Philipone EM; Peters SM
Head Neck Pathol; 2020 Dec; 14(4):1134-1138. PubMed ID: 32016785
[TBL] [Abstract][Full Text] [Related]
6. Multifocal primary pseudomyogenic hemangioendothelioma of bone managed with denosumab: A rare case with diagnostic and therapeutic challenge.
Pasricha S; Sharma A; Pruthi M; Durga G; Jajodia A; Gupta G; Kamboj M; Gupta M; Mehta A
J Cancer Res Ther; 2022; 18(3):817-819. PubMed ID: 35900565
[TBL] [Abstract][Full Text] [Related]
7. Spontaneously regressive multifocal bone pseudomyogenic hemangioendothelioma in a 17-year-old boy: a case report.
Maximen J; Christory A; Bonneau-Lagacherie J; Guillin R; Ropars M
Skeletal Radiol; 2023 Jan; 52(1):119-127. PubMed ID: 35780259
[TBL] [Abstract][Full Text] [Related]
8. An aggressive case of pseudomyogenic haemangioendothelioma of bone with pathological fracture and rapidly progressive pulmonary metastatic disease: case report and review of the literature.
Shah AR; Fernando M; Musson R; Kotnis N
Skeletal Radiol; 2015 Sep; 44(9):1381-6. PubMed ID: 25982253
[TBL] [Abstract][Full Text] [Related]
9. Primary pseudomyogenic hemangioendothelioma of bone: case report and review of the literature.
Squillaci S; Pitino A; Spairani C; Rassu PC; Chiapuzzo E; Kutzner H
Pathologica; 2018 Sep; 110(2):96-101. PubMed ID: 30546145
[TBL] [Abstract][Full Text] [Related]
10. A Case of Pseudomyogenic Hemangioendothelioma of the Lower Extremity.
Choi ME; Lim DJ; Chang SE; Lee MW; Choi JH; Lee WJ
Ann Dermatol; 2020 Oct; 32(5):426-429. PubMed ID: 33911779
[TBL] [Abstract][Full Text] [Related]
11. The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature.
Pranteda G; Magri F; Muscianese M; Pigliacelli F; D'Arino A; Federico A; Pranteda G; Bartolazzi A
Dermatol Ther; 2018 Nov; 31(6):e12725. PubMed ID: 30239066
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer.
Zhao N; Li X; He X; Qiu Y; Zhu L; Qi F
J Gene Med; 2013 Oct; 15(10):366-74. PubMed ID: 24038990
[TBL] [Abstract][Full Text] [Related]
13. Effective Use of Sirolimus and Zoledronic Acid for Multiosteotic Pseudomyogenic Hemangioendothelioma of the Bone in a Child: Case Report and Review of Literature.
Danforth OM; Tamulonis K; Vavra K; Oh C; Brickman A; Ebersole J; Cameron J; Mahon B; Kent P
J Pediatr Hematol Oncol; 2019 Jul; 41(5):382-387. PubMed ID: 31094908
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
15. Novel EGFL7-FOSB fusion in pseudomyogenic haemangioendothelioma with widely metastatic disease.
Hakar MH; White K; Hansford BG; Swensen J; Davis JL
Histopathology; 2021 Nov; 79(5):888-891. PubMed ID: 33550637
[No Abstract] [Full Text] [Related]
16. Primary Pseudomyogenic Hemangioendothelioma of Bone.
Inyang A; Mertens F; Puls F; Sumathi V; Inwards C; Folpe A; Lee CH; Zhang Y; Symmans P; Rubin B; Nielsen GP; Nguyen VH; Rosenberg AE
Am J Surg Pathol; 2016 May; 40(5):587-98. PubMed ID: 26872012
[TBL] [Abstract][Full Text] [Related]
17. Primary pseudomyogenic haemangioendothelioma of bone.
Sheng WQ; Wang J
Histopathology; 2012 Dec; 61(6):1219-24. PubMed ID: 22963723
[TBL] [Abstract][Full Text] [Related]
18. Epithelioid sarcoma-like (pseudomyogenic) hemangioendothelioma, clinically mimicking dermatofibroma, diagnosed by skin biopsy in a 30-year-old man.
Stuart LN; Gardner JM; Lauer SR; Monson DK; Parker DC; Edgar MA
J Cutan Pathol; 2013 Oct; 40(10):909-13. PubMed ID: 24033835
[TBL] [Abstract][Full Text] [Related]
19. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma.
Hung YP; Fletcher CD; Hornick JL
Am J Surg Pathol; 2017 May; 41(5):596-606. PubMed ID: 28009608
[TBL] [Abstract][Full Text] [Related]
20. Pseudomyogenic Hemangioendothelioma (Epithelioid Sarcoma-Like Hemangioendothelioma).
Caballero GA; Roitman PD
Arch Pathol Lab Med; 2020 Apr; 144(4):529-533. PubMed ID: 31017450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
